Subtopic Deep Dive

Electroporation Gene Therapy Delivery
Research Guide

What is Electroporation Gene Therapy Delivery?

Electroporation gene therapy delivery uses pulsed electric fields to create reversible pores in cell membranes for non-viral transfer of plasmid DNA, mRNA, or CRISPR into muscle, skin, and tumor tissues.

This method enhances transfection efficiency over naked DNA delivery, as shown in vivo studies on rat liver and muscle (Heller et al., 1996; Widera et al., 2000). Over 50 papers explore pulse parameters, electrode designs, and immune responses, with Widera et al. (2000) cited 598 times for DNA vaccine immunogenicity gains. Applications span vaccines, cancer therapy, and regenerative medicine.

Curated Papers

Key Challenges

Why It Matters

Electroporation boosts DNA vaccine potency in primates by improving cellular uptake, enabling clinical trials for infectious diseases (Widera et al., 2000). In tumor electrochemotherapy, it enhances drug and gene delivery, reducing internal tumor treatment times (Miklavčič et al., 2012). Liver-targeted delivery supports gene therapy for metabolic disorders, with efficiencies up to 100-fold higher than injection alone (Suzuki et al., 1998). These advances accelerate non-viral therapies, cutting viral vector risks in regenerative medicine.

Key Research Challenges

Optimizing Pulse Parameters

Balancing voltage, duration, and frequency for reversible pores without tissue damage remains critical. Sukharev et al. (1992) showed DNA-electropore interactions affect transfer efficiency. Tieleman (2004) modeled molecular mechanisms but in vivo translation varies by tissue type.

Minimizing Muscle Contractions

Conventional pulses cause painful contractions, limiting clinical use. Arena et al. (2011) introduced high-frequency irreversible electroporation (H-FIRE) to avoid this. Scaling H-FIRE for gene delivery needs further validation across tissues.

Enhancing In Vivo Immunogenicity

DNA vaccines underperform in large animals despite electroporation gains. Widera et al. (2000) improved immunogenicity but primate responses lag. Immune responses to electroporation itself complicate therapy outcomes.

Essential Papers

Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo

Georg Widera, Melissa A. Austin, Dietmar Rabussay et al. · 2000 · The Journal of Immunology · 598 citations

Abstract DNA vaccines have been demonstrated to be potent in small animals but are less effective in primates. One limiting factor may be inefficient uptake of DNA by cells in situ. In this study, ...

In vivo gene electroinjection and expression in rat liver

Richard Heller, Mark J. Jaroszeski, Andrew Atkin et al. · 1996 · FEBS Letters · 423 citations

In vivo targeted gene transfer by non‐viral vectors is subjected to anatomical constraints depending on the route of administration. Transfection efficiency and gene expression in vivo using non‐vi...

The molecular basis of electroporation

D. Peter Tieleman · 2004 · BMC Biochemistry · 420 citations

High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction

Christopher B. Arena, Michael B. Sano, John H. Rossmeisl et al. · 2011 · BioMedical Engineering OnLine · 341 citations

Electroporation and electrophoretic DNA transfer into cells. The effect of DNA interaction with electropores

Sergei Sukharev, Vadim A. Klenchin, S. M. Serov et al. · 1992 · Biophysical Journal · 319 citations

Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.

Shuichi Ikeyama, Masaru Koyama, M Yamaoko et al. · 1993 · The Journal of Experimental Medicine · 279 citations

Previously we showed that motility-related protein (MRP-1) is an antigen recognized by monoclonal antibody (mAb) M31-15 inhibiting cell motility and that the sequence of MRP-1 coincides with that o...

A Review on Electroporation-Based Intracellular Delivery

Junfeng Shi, Yifan Ma, Jing Zhu et al. · 2018 · Molecules · 239 citations

Intracellular delivery is a critical step in biological discoveries and has been widely utilized in biomedical research. A variety of molecular tools have been developed for cell-based gene therapi...

Reading Guide

Foundational Papers

Start with Widera et al. (2000) for in vivo DNA vaccine delivery benchmarks (598 citations), Heller et al. (1996) for liver protocols (423 citations), and Tieleman (2004) for molecular pore mechanisms (420 citations).

Recent Advances

Study Shi et al. (2018) review on intracellular delivery (239 citations) and Geng & Lu (2013) on microfluidic electroporation (211 citations) for modern device advances.

Core Methods

Core techniques: reversible electroporation with 100-1000V/cm pulses (Sukharev et al., 1992), H-FIRE bipolar waveforms (Arena et al., 2011), and in vivo needle arrays (Miklavčič et al., 2012).

How PapersFlow Helps You Research Electroporation Gene Therapy Delivery

Discover & Search

Research Agent uses searchPapers and citationGraph to map 598-citation foundational work like Widera et al. (2000) to recent reviews, revealing 250+ related papers via OpenAlex. exaSearch uncovers niche in vivo liver studies like Heller et al. (1996), while findSimilarPapers links pulse optimization papers to H-FIRE advances (Arena et al., 2011).

Analyze & Verify

Analysis Agent employs readPaperContent on Sukharev et al. (1992) to extract DNA-electropore models, then verifyResponse with CoVe checks claims against Tieleman (2004). runPythonAnalysis simulates pulse efficiencies using NumPy on transfection datasets, with GRADE scoring evidence strength for immunogenicity claims from Widera et al. (2000). Statistical verification quantifies 100-fold gains in Suzuki et al. (1998).

Synthesize & Write

Synthesis Agent detects gaps in muscle contraction mitigation between Arena et al. (2011) and gene delivery papers, flagging contradictions in immunogenicity. Writing Agent uses latexEditText and latexSyncCitations to draft protocols citing Heller et al. (1996), with latexCompile generating figures and exportMermaid visualizing electroporation workflows.

Use Cases

"Compare transfection efficiencies of electroporation pulses in rat liver models"

Research Agent → searchPapers('rat liver electroporation') → Analysis Agent → runPythonAnalysis(pandas on efficiencies from Heller 1996 + Suzuki 1998) → matplotlib plot of fold-increases.

"Draft LaTeX methods section for in vivo muscle electroporation protocol"

Synthesis Agent → gap detection (Widera 2000 protocols) → Writing Agent → latexEditText('insert pulse params') → latexSyncCitations(10 papers) → latexCompile → PDF with electroporation diagram.

"Find GitHub code for simulating electroporation pore formation"

Research Agent → paperExtractUrls(Tieleman 2004) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on molecular dynamics scripts.

Automated Workflows

Deep Research workflow scans 50+ electroporation papers, chaining citationGraph from Widera et al. (2000) to generate structured reports on vaccine delivery. DeepScan's 7-step analysis verifies H-FIRE claims (Arena et al., 2011) with CoVe checkpoints and Python-simulated ablation thresholds. Theorizer builds theories on DNA-electropore binding from Sukharev et al. (1992) and Tieleman (2004).

Try Doxa for Electroporation Gene Therapy Delivery Research

Frequently Asked Questions

What is electroporation gene therapy delivery?

It applies electric pulses to permeabilize cell membranes reversibly, enabling plasmid DNA or mRNA uptake in vivo for therapy. Key examples include muscle DNA vaccines (Widera et al., 2000) and liver transfection (Heller et al., 1996).

What are main methods in this subtopic?

Methods include square-wave pulses for reversible poration (Sukharev et al., 1992), H-FIRE for contraction-free delivery (Arena et al., 2011), and in vivo electrodes for tissue-specific transfer (Suzuki et al., 1998).

What are key papers?

Foundational: Widera et al. (2000, 598 citations) on vaccine immunogenicity; Heller et al. (1996, 423 citations) on liver electroinjection. Mechanisms: Tieleman (2004, 420 citations).

What open problems exist?

Challenges include scaling to humans without contractions, optimizing pulses per tissue, and sustaining immunogenicity in primates beyond Widera et al. (2000) gains.